乙型肝炎病毒(HBV)感染是肝炎、肝硬化、肝癌、肝功能衰竭的主要的推动因素。目前慢性乙型肝炎(CHB)治疗途径有多种,主要包括抗病毒、免疫调节、抗炎、抗氧化、抗纤维化和对症治疗;其中抗病毒治疗是治疗乙型肝炎的关键;核苷(酸)类似物及干扰素抗病毒效果明确。依据我国CHB防治指南(2010版)所提出的尽量避免单药序贯治疗,发现耐药要迅速给予联合用药。对CHB患者的抗病毒治疗,如符合以下条件,则应进行标 Hepatitis B virus (HBV) infection is a major driver of hepatitis, cirrhosis, liver cancer, and liver failure. At present, chronic hepatitis B (CHB) treatment has a variety of ways, including antiviral, immunomodulatory, anti-inflammatory, anti-oxidative, antifibrotic and symptomatic treatment; antiviral therapy is the key to the treatment of hepatitis B; Acid) analogues and interferon antiviral effect is clear. According to China’s guidelines for the prevention and treatment of CHB (2010 version) proposed to avoid sequential treatment of single drug, found that drug resistance should be promptly given combination therapy. Antiviral treatment of CHB patients, subject to the following conditions, should be marked